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Background: Oxidative stress plays a role in the pathogenesis of pre-eclampsia. Supplementing women with
antioxidants during pregnancy may reduce oxidative stress and thereby prevent or delay the onset pre-eclampsia.
The objective of this study was to evaluate the effect of supplementing vitamin C in pregnancy on the incidence of
pre-eclampsia, at Mulago hospital, Kampala, Uganda.
Methods: This was a (parallel, balanced randomization, 1:1) placebo randomized controlled trial conducted at Mulago
hospital, Department of Obstetrics and Gynecology. Participants included in this study were pregnant women aged
15-42 years, who lived 15 km or less from the hospital with gestational ages between 12-22 weeks. The women were
randomized to take 1000mg of vitamin C (as ascorbic acid) or a placebo daily until they delivered. The primary
outcome was pre-eclamsia. Secondary outcomes were: severe pre-eclampsia, gestational hypertension, preterm
delivery, low birth weight and still birth delivery. Participants were 932 pregnant women randomized into one of the
two treatment arms in a ratio of 1:1. The participants, the care providers and those assessing the outcomes were
blinded to the study allocation.
Results: Of the 932 women recruited; 466 were randomized to the vitamin and 466 to the placebo group. Recruitment
of participants was from November 2011 to June 2012 and follow up was up to January 2013. Outcome data was
available 415 women in the vitamin group and 418 women in the placebo group.
There were no differences in vitamin and placebo groups in the incidence of pre-eclampsia (3.1% versus 4.1%; RR 0.77;
95% CI: 0.37-1.56), severe pre-eclampsia (1.2% versus 1.0%; RR 1.25; 95% CI: 0.34-4.65), gestational hypertension
(7.7% versus 11.5%; RR 0.67; 95% CI: 0.43-1.03), preterm delivery (11.3% versus 12.2%; RR 0.92; 95% CI: 0.63-1.34),
low birth weight (11.1% versus 10.3%; RR 1.07; 95% CI: 0.72-1.59) and still birth delivery (4.6% versus 4.5%; RR 1.01;
95% CI: 0.54-1.87).
Conclusions: Supplementation with vitamin C did not reduce the incidence of pre-eclampsia nor did it reduce the
adverse maternal or neonatal outcomes. We do not recommend the use of vitamin C in pregnancy to prevent
pre-eclampsia.
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Hypertensive disorders in pregnancy are a leading cause
of maternal mortality worldwide [1] especially in low
resource settings [2]. Pre-eclampsia, defined by hyper-
tension and proteinuria, is a multisystem disorder which
is associated with, neurological disturbances, haemato-
logical disturbances, liver disease, and abnormal renal
function [3,4]. Pre-eclampsia affects 2-10% of all preg-
nancies and may be higher in low resource settings [5,6].
Severe pre-eclampsia may result in serious complica-
tions like eclampsia and the HELLP syndrome although
these complications are rare. In a study conducted in
Mulago hospital, pre-eclampsia/eclampsia contributed to
12% maternal deaths among women admitted with se-
vere maternal morbidity [7]. Pre-eclampsia contributes
to neonatal morbidity and mortality. Pre-eclampsia con-
tributed to 5.4% perinatal deaths and 24% of intrauterine
growth restriction [8] and is associated with 25.8% of
preterm births [9].Small-for-gestational age babies are
associated with health risks later in life like obesity and
insulin resistance, which may manifest as hypertension
and diabetes [10]. Preterm delivery is associated with
neonatal and infant mortality. Preterm infants are more
prone to respiratory complications like respiratory dis-
tress syndrome, transient tachypnea of the new born and
persistent pulmonary hypertension [11].
Antioxidants are essential in maintaining cellular in-
tegrity in normal pregnancy by reducing lipid peroxida-
tion reactions. Thus they protect proteins, enzymes, and
cells from destruction by peroxides. Antioxidant defense
mechanisms include intracellular and extracellular en-
zymes (viz. catalase, superoxide dismutase, glutathione
peroxidase), free radical scavengers (vitamin C & E, care-
tenoids, glutathione and serum albumin) and metabo-
lites (bilirubin and uric acid) [12].
The aetiology of pre-eclampsia is unknown. There is in-
complete trophoblast invasion of the spiral arteries [13]
which lead to abnormal placental development and, pla-
cental hypo perfusion and ischemia. Women with pre-
eclampsia have increased oxidative stress [14], increased
markers of oxidative stress like, 8-iso-prostaglandinF2α,
lipid peroxides [15] and, have low plasma and placental
concentration of antioxidants [12,16]. This has led to the
hypothesis that placental hypo perfusion may promote a
state of oxidative stress in which there is a release of fac-
tors to the maternal circulation [13,17]. The factors in-
clude, lipid peroxides, cytokines and syncitiotrophoblast
microvillus fragments [18] which are highly reactive mole-
cules that consume the antioxidants.
Oxidative stress combined with an exaggerated inflam-
matory response may result in the release the maternal
factors that cause endothelial dysfunction [18]. Endothelial
cell dysfunction is responsible for the clinical signs of pre-
eclampsia like hypertension and protienuria. Response tooxidative stress depends on availability of low density lipo-
proteins, genetic predisposition, immune mal-adaptation
[19] and dietary deficiency of antioxidants [20]. Supple-
mentation with antioxidants may modify the women’s re-
sponse to oxidative stress and therefore limit the systemic
and utero-placental endothelial damage observed in pre-
eclampsia.
Vitamin C scavenges free radicals in aqueous solution
and may have a role in the management of pre-eclampsia.
Studies show that vitamin C may be protective against de-
velopment of pre-eclampsia [21,22]. Supplementation with
vitamin C and E reduces oxidative stress and endothelial
dysfunction [23] and, pre-eclampsia [24]. However, subse-
quent studies have not confirmed this [25-27]. Most of
these studies were conducted in high resource settings
where the nutritional status of the women is high.
The purpose of this study therefore was to evaluate
the effects of vitamin C supplementation on the occur-
rence of pre-eclampsia in a low resource setting where
the nutritional status of the women is low and most
pregnant women are deficient in vitamin C [28].
Methods
Trial design
This was a (parallel, balanced randomization, 1:1,) pla-
cebo controlled trial conducted from November 2011 to
January 2013, in Uganda.
Participants
Participants included in this study were pregnant women
aged 15-42 years, lived 15 km or less from the hospital
with gestational ages between 12-22 weeks. Women were
excluded if they had hypertension, renal diseases or dia-
betes mellitus, were taking vitamin C supplements of >200
mg/day or had contraindications to vitamin C.
Setting
This study was conducted at Mulago Hospital, Department
of Obstetrics and Gynaecology. Mulago Hospital is a
National Referral Hospital for Uganda and a Teaching
Hospital for Makerere University College of Health Sciences.
In Uganda about 90% of the women attend antenatal
clinic at least once during pregnancy. Mulago hospital de-
livers about 22,000 women annually and about 50,000
women attend antenatal clinic in 1 year.
Interventions
The women were randomized in one of the two treatment
arms using computer generated random numbers in a ra-
tio of 1:1. The women allocated to the vitamin arm were
advised to take a tablet of 1000 mg of vitamin C (as ascor-
bic acid) daily until they delivered. The women allocated
to the placebo arm were advised to take a placebo tablet
(micro-crystalline cellulose) daily which was identical to
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swallow the tablets daily and leave the unused tablets.
Study procedures
Eligible women were identified from the antenatal clinic
by research assistants who were trained midwives. The
women were conducted through an informed consent
procedure and gave a written informed consent. The
women were interviewed about their socio-demographic
characteristics, medical and family history, and their
present and past obstetric performances. A thorough
clinical and obstetrical examination was done, weight
was taken and height measured. A mid upper arm cir-
cumference was measured by a trained assistant. Blood
was drawn for complete blood counts, renal and liver
function tests and HIV screening.
Follow up
All the women were followed until they delivered. The
study participants received care according the Uganda
Ministry of Health guidelines. Routine visits were done
by the research team every four weeks until the women
delivered. If a woman missed the scheduled visit she was
contacted by telephone and visited at her home and, if
necessary was transported to hospital for evaluation by
the study physicians. During the routine assessments the
women were asked about compliance with the study
medication, condition of their health, and if they had vis-
ited other heath facilities and the medications they had
taken. In addition they had a focused history and, obstet-
ric examination using a standard clinical record form. At
each visit the blood pressure of the women was mea-
sured using a mercury sphygmomanometer. Two blood
pressure measurements were taken and an average was
obtained. If a woman had a high blood pressure a mid-
stream urine sample was collected for protein estimation
using a dipstick. All the women received oral iron and
folic acid supplements which they took daily and, de-
worming tablets and intermittent presumptive treatment
for malaria according to the Uganda Ministry of Health
guidelines.
The women who developed hypertension were man-
aged according to the protocol of the hospital.
Outcomes
The primary end point was development of pre-eclampsia
in the mother. The secondary outcomes were develop-
ment of severe pre-eclamsia and gestational hypertension
in the mother and, in the infant were low birth weight, still
birth delivery and preterm delivery.
Pre-eclampsia was defined as described by the International
Society for the Study of Hypertension in Pregnancy [29].
Under this classification, hypertension was defined as
a blood pressure of ≥140/90 mmHg measured with a womanin a sitting position using a mercury sphygmomanometer.
The blood pressure was repeated after 4 hrs. Significant
proteinuria was taken as ≥2+ protein on dipstick of mid
stream urine or catheter specimen urine if membranes
were ruptured on two urine specimens 4 hrs or more
apart. Pre-eclampsia was taken as hypertension with sig-
nificant proteinuria, after 20 weeks gestation.
A woman was taken to have severe pre-eclampsia if she
developed one or more of the following: a blood pressure
of ≥160 mmHg systolic or ≥110 mmHg diastolic, ≥3+ pro-
tein by dipstick on two urine samples taken four hours or
more apart, visual disturbances, frontal or any type of
headache, epigastric or right upper quadrant pain, pul-
monary oedema or cyanosis, abnormal liver function, low
platelets, oliguria of less than 500 ml in 24 hours and fetal
growth restriction [30].
Gestational hypertension was defined as hypertension
which developed after 20 weeks of pregnancy in a woman
who previously had a normal blood pressure and the
blood pressure reverted to normal after delivery.
Low birth weight was defined as delivery of a baby
whose birth weight was less than 2500 gm. A still birth
was defined as delivery of a baby which died in uterus
after 24 weeks of pregnancy. Preterm delivery was taken
as delivery before 37 weeks of gestation.Sample size
We assumed that supplementation with vitamin C would
lower the risk of pre-eclampsia by 50% compared to a pla-
cebo. We estimated the risk of pre-eclampsia to be 10% in
the placebo arm based on the literature [31-33] and
Mulago Hospital, Department of Obstetrics and Gynae-
cology annual reports [34]. Given these estimates a sample
size of 932 women would give a power of 80% at 95% con-
fidence level.Interim analyses and stopping guidelines
We performed one interim analysis when the accumulat-
ing data had accrued approximately half the estimated
sample size according to O’Brien-Fleming boundaries
(DeMets error-spending function) at a level α = 0.05
(two sided); the significance level for the final analysis was
α = 0.0459. A standardized test statistic was calculated for
the incidence of pre-eclampsia and all adverse effects
based on accrued data. The Data Safety and Monitoring
Board recommended continuation of the study.Randomization: sequence generation
An independent pharmacist allocated the active tablets
or placebo tablets according to the computer generated
randomization list. The study participants were given
drugs every month until they delivered.
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The randomization sequence was created using stata 12
software package in ratio of 1:1. Permutated block size of
6 and 8 were used and these were varied at random.
Randomization: allocation concealment
The vitamin C and placebo tablets were identical in size,
shape and colour. The study medications were packed in
sealed white opaque bottles and were consecutively num-
bered for each woman according to the randomization
schedule by a researcher who was not involved in the re-
cruitment or clinical care.
Randomization: implementation
The randomization was done by an independent statisti-
cian who was not involved in the study. Computer gen-
erated randomization codes were used to generate the
randomization list which were sent to the pharmacy.
The women were allocated a study number by the re-
search assistants who recorded the enrollment date and
escorted the women to the pharmacy to receive the treat-
ment assignment code and received the study medications.
Blinding
The participants, the care providers and those assessing
the outcomes were blinded to the study allocation.
Similarity of interventions
Rene Industries Ltd. (Kireka, Kampala, Uganda) prepared
vitamin C (ascorbic acid) and identical placebo tablets
(microcrystalline cellulose). The tablets were identical in
color, shape and size.
Statistical methods
The Data were cleaned, coded and double entered using
EPIDATA version 3.1 statistical package and transferred
to STATA version 12 for analysis. Analyses were done
using intention-to-treat principle: all randomly assigned
groups were included in the group to which they were
initially assigned. Women who were lost to follow-up
were not included in the analyses of outcomes. Continu-
ous variables were compared using a t-test and categor-
ical variables between groups were compared using Chi
squared test. Risks of the outcomes of interest were cal-
culated and compared between the treatment and con-
trol arms. The results are presented as risk ratios with
the corresponding 95% confidence intervals. Adjusted
analyses were not done since the groups were compar-
able at baseline. This trial is registered as Pan African
Clinical Trial, Registry PACTR 2012100000418271.
Ethical approval
This study was approved by the Makerere University College
of Health Sciences Ethics Committee, The Mulago HospitalEthics Committee, The National Council for Science and
Technology in Uganda and the Uganda National Drug
Authority. The women gave written informed consent.Results
We screened 1,097 women, of which 956 were eligible
but 932 women were willing to participate in the study
and were randomized (466(50%) to the vitamin C group
and 466(50%) to the placebo group). The losses to
follow-up were 51(10.9%) women in the vitamin group
and 48(10.3%) women in the placebo group (Figure 1).
Recruitment started in November 2011 and was com-
pleted in June 2012.
The enrollment and randomization of the women is as
shown in Figure 1 below according to the flow chart
suggested by the Consolidated Standards of Reporting
Trials (CONSORT) [35].Recruitment
Eligible participants were recruited from November
2011 to June 2012. Participants attended the clinic at the
time of randomization (baseline) and at four weekly in-
tervals until January 2013.Baseline data
The baseline characteristics are shown in Table 1. There
were no differences in the participants’ baseline charac-
teristics (viz. age, educational level, marital status, parity,
alcohol consumption, HIV status, smoking status, book-
ing gestational age and booking blood pressure) at
randomization.Numbers analyzed
The primary analysis was by intention-to-treat and pa-
tients were analyzed in the groups in which they were
randomly assigned. Fifty one women in the vitamin
group were lost to follow up, therefore 415 women were
available for the analysis of outcomes; meanwhile 48
women were lost to follow up in the placebo group and
418 women were available for analysis of outcomes.
Eight women in the vitamin group and 6 women in the
placebo group had changed their residences; the rest of
the women could not be traced by telephone. There
were no differences in the demographic characteristics
in the women who were lost to follow up (Table 2).
There were no differences in the baseline characteristics
between the women who were lost to follow up and the
women who turned up.
Compliance was assessed as the percentage of tablets
consumed over the total number of tablets supplied. Com-
pliance was similar in both groups (median 85%).
Figure 1 Trial profile.
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The primary outcome was the incidence of pre-eclampsia.
Pre-eclampsia was 3.1% in the vitamin group and 4.1% in
the placebo group (RR: 0.77; 95% CI 0.37-1.56) (Table 3).
The secondary maternal outcomes were: severe pre-
eclampsia 1.2% in the vitamin and 1.0% in the placebo
group (RR: 1.25; 95% CI: 0.34-4.65) and gestational hyper-
tension 7.7 in the vitamin and 11.5 in the placebo group
(RR: 0.67; 95% CI: 0.43-1.03). Other maternal outcomes:
ante partum haemorrhage, premature rupture of mem-
branes and abruption placenta were similar in both groups
(Table 3). There were two cases of eclampsia in the pla-
cebo group.
Overall, the incidence of pre-eclampsia was 3.6% (30/
833). The incidence was 1.9% (4/215) among primigrav-
idae, 2.3% (8/350) among gravida two to three, and 6.7%
(18/268) among women who were gravida four or more
(Table 4).
The secondary neonatal outcomes were low birth weight,
still birth delivery and preterm delivery. The low birth
weight rate was 11.1% in the vitamin group and 10.3% in
the placebo group (RR: 1.07; 95% CI: 0.72-1.59), the still
birth rate was 4.6% in vitamin group and 4.5% in the pla-
cebo group (RR: 1.01, 95% CI: 0.54-1.87) and preterm de-
livery was 11.3% in the vitamin C group and 12.2% in theplacebo group (RR: 0.92; 95% CI: 0.63-1.34) There were
no differences in the other neonatal outcomes between
the groups (Table 5).
Discussion
This study was a randomized placebo controlled trial in
which antioxidant vitamin C was given to healthy preg-
nant women daily from the second trimester until they
delivered to reduce the risk of pre-eclampsia. Supple-
mentation with high doses of vitamin C did not reduce
the risk of pre-eclampsia. This is in contrast with an
earlier study by Chappell and colleagues [24] which in-
vestigated the effect of 1000 mg of vitamin C and 400 IU
of vitamin E on 239 women from 18-22 weeks gestation
until delivery on the risk of pre-clamspia. The incidence
of pre-eclampsia was 8% in the supplemented group
versus 17% in the placebo group. However, in this study
pre-eclampsia was a secondary outcome and the study
was stopped early because the interim analysis indicated
that there was significant improvement in the markers
of endothelial activation which was the primary outcome
and thus there were only 79 women in the vitamin group
who completed the study versus 142 in the placebo arm.
There could have been type I error since the sample size
was small.






n (%) n (%)
Age group (years)
0.77
≤19 91 (19.5) 98 (21.0)
20-29 247 (53.0) 253 (54.3)
30-34 79 (17.0) 69 (14.8)
≥35 49 (10.5) 46 (9.9)
Marital status
0.12Married 403 (86.5) 386 (82.8)
Single 63 (13.5) 80 (17.2)
Educational level
0.41Primary or less 186 (39.9) 174 (37.3)
Secondary or above 280 (60.1) 292 (62.7)
Parity
0.86
Primigravidae 135 (29.0) 129 (27.7)
Gravida 2-3 187 (40.1) 186 (39.9)
Gravida ≥4 144 (30.9) 151 (32.4)
Alcohol consumption
0.8
Yes 41 (8.8) 39 (8.4)
HIV status
0.42Positive 39 (8.4) 46 (9.9)
Negative 427 (91.6) 420 (90.1)
Smoking
0.99
Yes 1 (0.2) 1 (0.2)
*Booking gestational age 19.3 (SD 3.8) 19.7 (SD 4.0)
*Booking systolic BP (mmHg) 113.9 (SD 12.8) 114.9 (SD 14.1)
*Booking diastolic BP (mmHg) 67.5 (11.4) 68.1 (11.2)
Hypertension in family
0.31
Yes 64 (13.7) 75 (16.1)
*These are presented as means (standard deviations). BP: Blood pressure, HIV: Human
Immunodeficiency Virus. For binary variable only yes category was reported.
Table 2 Characteristics of women lost to follow up in the
clinical trial
Characteristic Vitamin C N = 51 Placebo N = 48 P value
n (%) n (%)
Age group (years)
0.4
≤19 17 (33.3) 21 (43.7)
20-29 21 (41.2) 21 (43.7)
30-34 6 (11.8) 3 (6.3)
≥35 7 (13.7) 3 (6.3)
Marital status
0.5Married 37 (72.6) 32 (66.7)
Single 14 (27.4) 16 (33.3)
Educational level
0.6Primary or less 25 (49) 26 (54)
Secondary or above 26 (51) 22 (46)
Parity
0.8
Primigravidae 24 (47.0) 25 (52.1)
Gravid 2-3 13 (25.5) 10 (20.8)
Gravid ≥4 14 (27.5) 13 (27.1)
Alcohol consumption
0.3
Yes 2 (3.9) 4 (8.3)
HIV status
0.7Positive 4 (7.8) 3 (6.3)
Negative 47 (92.2) 45 (93.7)
Hypertension in family
0.6
Yes 7 (13.7) 8 (16.7)
HIV: Human immunodeficiency virus.
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to be of benefit were epidemiological studies. Zhang and
colleagues [36] conducted a case-control study in which
women with a low intake of vitamin C were at an in-
creased risk of pre-eclampsia. There could have been a re-
call bias by the women and the study design could not
establish a cause-effect relationship. Similarly, Klemmen-
sen and others [22] conducted a prospective population
based cohort study in which women with a low dietary in-
take of vitamin C were found to have an increased risk of
severe forms of pre-eclampsia. There could have been a
misclassification of pre-eclampsia and other hypertensive
diseases in pregnancy since the case ascertainment were
a self report by the women. There could have also been
a recall bias by the women on the food consumption and
hence the evaluations of the vitamin C intake may not
have been accurate.However, the finding in our study is in agreement with
what found by other researchers about use of antioxi-
dants to prevent pre-eclampsia [25-27,37]. Beazley and
colleagues [25] studied the use of antioxidants among
women at increased risk of pre-eclampsia. They did not
find a difference in the incidence of pre-eclampsia
among women who received antioxidants and placebo
group. However, this study was terminated early because
of lack of funding and the required sample size was not
realized. Rumbold and colleagues [26] studied low risk
women with a high nutritional status in which high dose
vitamin C and vitamin E were given from second trimester
until delivery. There was no reduction in pre-eclampsia
between the two groups. In this study, the women’s base-
line intake of vitamin supplements was above the recom-
mended daily intake. In a study by Poston and collegues
[37], women who were at an increased risk of pre-
eclampsia were supplemented with high doses of vitamin
C and vitamin E from the second trimester until they de-
livered. There was no reduction in the incidence of pre-
eclampsia between the two groups.
Table 3 Maternal outcomes between the vitamin and placebo groups
Characteristic Vitamin C Placebo Risk ratio P value
N = 415 N = 418
Pre-eclampsia
Yes 13 (3.1) 17 (4.1) 0.77 (0.37-1.56) 0.4
Severe pre-eclampsia
Yes 5 (1.2) 4 (1.0) 1.25 (0.34-4.65) 0.72
Gestational hypertension
Yes 32 (7.7) 48 (11.5) 0.67 (0.43-1.03) 0.06
Ante partum haemorrhage
Yes 7 (1.7) 9 (2.2) 0.78 (0.29-2.1) 0.6
Premature rupture of membranes
Yes 15 (3.6) 19 (4.6) 0.79 (0.41-1.54) 0.5
Abruption
Yes 1 (0.2) 2 (0.5) 0.5 (0.04-5.53) 0.6
Delivery route
Vaginal 278 (67.0) 281 (67.2) 1.0 (0.82-1.22) 0.9
Caesarean 137 (33.0) 137 (32.8)
Twin delivery
Yes 14 (3.4) 11 (2.6) 1.28 (0.59-2.79) 0.5
Eclampsia
Yes 0 (0) 2 (0.5) 0
For binary variable, only the Yes category has been reported.
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aetiology of pre-eclapmsia [15,38,39], and women with
pre-eclampsia have increased markers of oxidative stress
in the plasma and in the placenta [13]. However, results
from this study and others indicate that use of high
doses of antioxidants during pregnancy does not reduce
the risk of pre-eclampsia. The explanation for this finding
may be that while oxidative stress is present in women
with pre-eclampsia, it may not play an important role in
the pathophysiology of the disorder. It may also be pos-
sible that oxidative stress plays a role only in a subgroup
of women with no appreciable effect on the general popu-
lation. It also is possible that the women in our study had
sufficient concentrations of vitamin C at trial entry. We
based our assumptions on a previous study [40] in whichTable 4 Incidence of pre-eclampsia in the different parities
Characteristic Pre-eclampsia 95% CI
Parity n (%)
Primegravidae 4 (1.8) 0.5-4.6
Gravida 2-3 8 (2.3) 0.9-4.6
Gravida ≥4 18 (6.7) 4.0-10.4
Total 30 (3.6)
CI: Confidence Interval.most women were deficient of vitamin C. However, doses
of vitamin C of 400 mg per day or higher result in plasma
and tissue saturation and produces a steady-plasma con-
centration. When vitamin C doses of 500 mg per day or
higher are given, the extra absorbed vitamin C is excreted
to produce a steady plasma and tissue concretions [41].
Even in women who were at high risk of pre-eclampsia
and nutritionally deficient [27], the antioxidants did not
reduce the risk of pre-eclampsia.
In this paper the rate of severe pre-eclampsia was simi-
lar in intervention and placebo groups. This is similar to
what was found in other studies among high risk women
[24,27,37,42] and women at low risk [43]. Similarly the
rate of gestational hypertension did not differ between the
intervention and placebo group. This is in agreement
with was found by Villar and colleagues [27] in high risk
women but is in contrast to what was found by Poston
and colleagues [37] in high risk women and Roberts and
colleagues [43] in low risk women in which women who
took antioxidants were more likely to develop gestational
hypertension than the controls. In addition, Poston and
colleagues [37] and Rumbold and colleagues [26] found
that women who took antioxidants were more likely to
use antihypertensive therapy than controls. This was prob-
ably due to chance, but antioxidants may promote DNA
oxidation through an interaction between vitamin C and





Risk ratio P value
n (%) n (%)
Birth weight
0.7<2500 gm 46 (11.1) 43 (10.3) 1.07 (0.72-1.59)
≥2500 gm 369 (88.9) 375 (89.7)
Apgar score
0.4<7 41 (9.9) 35 (8.4) 1.17 (0.76-1.81)
≥7 374 (90.1) 383 (91.6)
Admission to special care unit
0.07
Yes 41 (9.9) 27 (6.5) 1.53 (0.95-2.43)
Still birth
0.9
Yes 19 (4.6) 19 (4.5) 1.01 (0.54-1.87)
Early neonatal death
0.4
Yes 7 (1.7) 10 (2.4) 0.71 (0.27-1.83)
Abortion
0.9
Yes 9 (2.2) 9 (2.2) 1.01 (0.40-2.51)
Preterm delivery
0.7
Yes 47 (11.3) 51 (12.2) 0.92 (0.63-1.34)
For binary categories, only the yes category was reported.
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stress and, may produce mutagenic lesions in DNA [45].
In our study the low birth weight delivery rate was
similar in the both the vitamin and placebo groups. This
is in agreement with a study by Roberts and colleagues
[43] in low risk women and Spinnato and colleagues
[42] and, Villar and colleagues [27] in high risk women,
in which the rates of low birth weight delivery was simi-
lar in the antioxidant and placebo group. But it differs
from what was found by Poston and colleagues [37] in
high risk women in which women who were supple-
mented with antioxidants were more likely to deliver low
birth weight babies than the controls. This could be be-
cause the women who took supplements developed pre-
eclampsia earlier and hence delivered at an earlier
gestational age. An earlier study showed that vitamin C
supplements given during pregnancy were associated with
preterm delivery than controls [46] although this did not
translate in poorer neonatal outcomes. However, this was
more likely to be a chance finding as more women in this
group had a previous history of miscarriage and ante par-
tum haemorrhage.
In our study preterm delivery was similar between the
intervention and control groups. This is similar to what
was found in another study of intervention with antioxi-
dants in high risk [27,42] and low risk women [43]. The
rate of still birth delivery was similar in intervention and
control group. This similar to what was found by Roberts
and colleagues [43] and Rumbold and colleagues [26] inlow risk women and by Spinnato and colleagues [42]
and by Villar and colleagues [27] in high risk women.
However, post hoc analyses in the Rumbold and col-
leagues [26] study showed more still birth delivery in
women who took antioxidants than the controls. How-
ever, the still birth rate was extremely high among women
in this study. This could have been be due to delay of
the women to reach the hospital after labour had started
and institutional delay especially for women who needed
caesarean section as the waiting time on average was 4-6
hours.
The other maternal outcomes (viz. ante partum haem-
orrhage, premature rupture of membranes, abruption pla-
centae, mode of delivery) and neonatal outcomes (viz.,
apgar score, admission to the baby neonatal unit, early
neonatal death) did not differ between the intervention
and placebo groups.
Limitations
This study was conducted in the national referral hos-
pital and some findings may not be generalized to all
pregnant women in Uganda. The incidence of pre-
eclampsia was lower than was initially anticipated. This
could have led to estimation of a smaller sample size.
Therefore the results should be interpreted with caution
as they may not be generalized to all pregnant women
because of type II error. However, this study has enabled
us to establish the effects of vitamin C supplementation
on other pregnancy outcomes in Uganda.
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Supplementation with high dose vitamin C did not reduce
the risk of pre-eclampsia nor did it reduce the risk of low
birth weight delivery, still birth delivery and preterm deliv-
ery in low risk women with poor nutritional status in our
institution. We do not recommend the use of high dose
vitamin C in pregnancy to prevent pre-eclampsia or other
adverse maternal and neonatal outcomes.
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